Monjuvi Tafasitamab: Targeted Therapy for Relapsed Lymphomas

Monjuvi (tafasitamab-cxix), a CD19-directed monoclonal antibody, treats relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma in adults, offering new options where standard therapies fail.

Monjuvi (tafasitamab-cxix) delivers targeted treatment for patients with hard-to-treat blood cancers, binding specifically to CD19 on malignant B-cells to trigger cell destruction.

The therapy combines with lenalidomide and rituximab for relapsed or refractory follicular lymphoma after at least one prior systemic therapy. It also holds accelerated approval for diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Updated: 05/14/2026

By Dr. Elena Vargas, Senior Biotech Editor - covering oncology therapeutics and global pharmaceutical markets.

At a Glance

• Product: Monjuvi (tafasitamab-cxix)
• Category: Monoclonal Antibody
• Brand/Manufacturer: Incyte / MorphoSys
• Primary Use Cases: Relapsed/refractory follicular lymphoma, DLBCL
• Availability: US, Europe (as Minjuvi), Japan
• Key Markets: Oncology, hematology

What Monjuvi (Tafasitamab-cxix) Is and How It Works

Monjuvi is a humanized Fc-modified cytolytic monoclonal antibody targeting CD19, a protein expressed on B-cells including those in certain lymphomas. Unlike standard antibodies, its engineered Fc domain enhances antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and complement-dependent cytotoxicity.

The mechanism destroys cancer cells through multiple immune pathways. It binds CD19, recruiting natural killer cells and macrophages to attack lymphoma cells. Clinical data from the L-MIND study showed an overall response rate of 60% in relapsed/refractory diffuse large B-cell lymphoma patients, with 40% achieving complete response.

In combination regimens, Monjuvi pairs with immunomodulatory agents like lenalidomide, which boosts T-cell and NK-cell activity, and rituximab, another CD20-targeted antibody, for synergistic effects in follicular lymphoma.

Why Monjuvi Matters for Patients and Oncology

For adults with relapsed follicular lymphoma after initial treatments fail, Monjuvi offers a chemotherapy-free option. FDA approval in combination with lenalidomide and rituximab addresses a gap for stage 1-3a patients ineligible for or progressed after frontline therapy.

In diffuse large B-cell lymphoma, accelerated approval targets those not candidates for autologous stem cell transplant (ASCT). This expands access to targeted therapy, potentially delaying or avoiding more toxic interventions. European approval as Minjuvi and Japanese nod further affirm its global role in B-cell malignancies.

Over 20 abstracts on tafasitamab at recent congresses highlight ongoing research into combinations and new indications, underscoring its evolving importance in precision oncology.

Monjuvi in the Global Oncology Market

Monjuvi competes in the crowded relapsed lymphoma space against CAR-T therapies like Yescarta and bispecific antibodies like Epkinly, but stands out for outpatient administration without specialized centers. Its fixed-duration cycles (up to 12 months) improve patient convenience over continuous therapies.

Regulatory milestones include FDA approval for follicular lymphoma on 04/25/2025 in combination with lenalidomide and rituximab, building on prior DLBCL nod. In Europe, Minjuvi approval covers similar follicular lymphoma use, while Japan approves it with rituximab and lenalidomide for second-line plus relapsed cases.

Supply chains rely on biotech manufacturing for monoclonal antibodies, with Incyte handling US commercialization and MorphoSys supporting global development. Demand trends reflect growing incidence of B-cell lymphomas, with follicular cases comprising about 20% of non-Hodgkin lymphomas.

Incyte Corporation markets Monjuvi in the United States, partnering with MorphoSys AG for development and ex-US rights. MorphoSys originated the antibody through its HuCAL technology platform.

Monjuvi trades under Incyte sponsorship, with MorphoSys listed on the Frankfurt exchange under ISIN DE0006632003.

Disclaimer: This article is not investment advice. Stocks are volatile financial instruments.